Pharmaceutical company Roche is entering the fight against obesity with the $2.7 billion (CHF2.3 billion) takeover of United States firm Carmot Therapeutics.
This content was published on
2 minutes
Keystone-SDA
Español
es
Roche declara la guerra a la obesidad con una adquisición multimillonaria
Milestone payments of up to $400 million can also be made. According to Monday’s announcement, Carmot Therapeutics is privately held and has in its pipeline product candidates that can be used to treat obesity in patients with and without diabetes. They are all based on the novel GLP-1 mechanism of action, which has recently been the subject of a lot of media attention.
Recently, the drug Wegovy caused a stir. It is a product from the Danish pharmaceutical company Novo Nordisk. It contains the active ingredient semaglutide, which promotes weight loss in people who are very overweight.
Wegovy, for example, has to be injected under the skin once a week. In people with obesity without additional diabetes, Wegovy therapy can lead to a weight reduction of up to 15 percent over a treatment period of 18 months. In principle, Wegovy increases the feeling of satiety, which reduces the calories consumed because patients simply have less hunger and appetite.
Other products in this area include Ozempic, also from Novo Nordisk, or Eli Lilly’s diabetes drug Mounjaro, which also ensures weight loss.
With the takeover of Carmot, Roche is now adding three important GLP-1 product candidates to its portfolio. Two of the candidates will be tested to treat obesity in patients with and without type 2 diabetes, while the third will be used to treat type 1 diabetes patients who are overweight or obese.
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles. You can find them here.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
Diversity and equality ‘under threat’: ex-Swiss minister
This content was published on
Dismantling diversity programmes is a backwards step for equality, warns former Swiss government minister Simonetta Sommaruga.
Swiss regulator fines US bank Citi over fat-finger crash
This content was published on
Citigroup fined CHF500,000 by Swiss stock exchange regulator after a fat-finger trade caused a 2022 flash crash in European stocks.
Swiss steel industry offered four-year state subsidies
This content was published on
Strategically important steel companies in Switzerland are eligible for state aid from the start of this year until the end of 2028.
Swiss companies failing to observe equal pay obligations
This content was published on
Many Swiss companies are failing to carry out their legal obligation to monitor equal pay, says the Federal Office of Justice.
This content was published on
The Swiss Federal Supreme Court has overturned the conviction of a commodities trader who had been given a suspended sentence and fined CHF72 million.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.